The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge

Lancet Breast Cancer Commission

doi:10.1016/S0140-6736(22)00184-2

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge

Lancet Breast Cancer Commission

Résultats de recherche: Contribution à un journal › !!Comment/debate

19 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1101-1103
Nombre de pages	3
journal	The Lancet
Volume	399
Numéro de publication	10330
Les DOIs	https://doi.org/10.1016/S0140-6736(22)00184-2
état	Publié - 19 mars 2022

Accès au document

10.1016/S0140-6736(22)00184-2

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{779f6ab80e764e2087c0842590cca28c,

title = "The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge",

author = "{Lancet Breast Cancer Commission} and Coles, {Charlotte Elizabeth} and Anderson, {Benjamin O.} and David Cameron and Fatima Cardoso and Richard Horton and Knaul, {Felicia Marie} and Miriam Mutebi and Naomi Lee and Abraham, {Jean E.} and Fabrice Andr{\'e} and Barrios, {Carlos H.} and Bliss, {Judith M.} and Boughey, {Judy C.} and Cameron, {David A.} and Cardoso, {Fatima V.} and Carey, {Lisa A.} and Sanjoy Chatterjee and Jack Cuzick and {Du Plooy}, Dorothy and Francis, {Prudence A.} and Gralow, {Julie R.} and Reshma Jagsi and Fei Ma and Mann, {Ritse M.} and McIntosh, {Stuart A.} and Mertz, {Shirley A.} and Funmi Olopade and Phillips, {Kelly Anne} and Poortmans, {Philip M.} and Tanja Spanic and Dingle Spence and Hilary Stobart and Symmans, {Fraser WF} and Cynthia Villarreal-Garza and Yip, {Cheng Har} and Bienz, {Maya J.} and Drewett, {Lynsey M.} and Alex Fulton and {Inbah Rajah}, Dharrnesha and Farasat Kazmi and Jeffrey Rubasingham and Mareike Thompson and Valentina Vargas and Hector Arreola and Badwe, {Raj A.} and {Calderon Anyosa}, {Renzo JC} and Dave, {Rajiv V.} and {De-Graft Aikins}, Ama and Earl, {Helena M.} and Essue, {Beverley M.}",

note = "Funding Information: CEC is funded by the National Institute of Health Research (NIHR) and supported by the NIHR Cambridge Biomedical Research Centre. DC reports non-financial interactions unrelated to this Comment with Exact Sciences, Novartis, Lilly, Syntheon, GRAIL, AstraZeneca, Sanofi, Roche, Pfizer, Daiichi-Sankyo, SeaGen, Bexon Consulting, Sapience Therapeutics, and Cytel; research funding unrelated to this Comment, paid to his institution or other institutions, from Amgen, AstraZeneca, Novartis, PFS Exact Sciences, Pfizer, and Roche; and personal fees from AIRC, INCA, SABCS, and Terry Fox Research Institute unrelated to the topic of this Comment. FC reports personal fees from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Debiopharm, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck Sharpe & Dohme, Merus, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, priME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, and Touchime unrelated to the topic of this Comment. FMK is the founding president of T{\'o}matelo a Pecho, a Mexican non-governmental organisation (NGO), and works in a volunteer capacity; T{\'o}matelo a Pecho receives funding from Merck Sharpe & Dohme and Higia. FMK is the senior economist of the Mexican Health Foundation, a Mexican NGO, which receives funding from Fundaci{\'o}n Gonzalo R{\'i}o Arronte, and reports consulting fees from Merck KGaA/EMD Serono unrelated to the topic of this Comment. BOA, RH, MM, and NL declare no competing interests. Financial support for Commission meetings and reimbursement for patient advocates has been provided by Breast Cancer Now. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or WHO. ",

year = "2022",

month = mar,

day = "19",

doi = "10.1016/S0140-6736(22)00184-2",

language = "English",

volume = "399",

pages = "1101--1103",

journal = "The Lancet",

issn = "0140-6736",

number = "10330",

}

TY - JOUR

T1 - The Lancet Breast Cancer Commission

T2 - tackling a global health, gender, and equity challenge

AU - Lancet Breast Cancer Commission

AU - Coles, Charlotte Elizabeth

AU - Anderson, Benjamin O.

AU - Cameron, David

AU - Cardoso, Fatima

AU - Horton, Richard

AU - Knaul, Felicia Marie

AU - Mutebi, Miriam

AU - Lee, Naomi

AU - Abraham, Jean E.

AU - André, Fabrice

AU - Barrios, Carlos H.

AU - Bliss, Judith M.

AU - Boughey, Judy C.

AU - Cameron, David A.

AU - Cardoso, Fatima V.

AU - Carey, Lisa A.

AU - Chatterjee, Sanjoy

AU - Cuzick, Jack

AU - Du Plooy, Dorothy

AU - Francis, Prudence A.

AU - Gralow, Julie R.

AU - Jagsi, Reshma

AU - Ma, Fei

AU - Mann, Ritse M.

AU - McIntosh, Stuart A.

AU - Mertz, Shirley A.

AU - Olopade, Funmi

AU - Phillips, Kelly Anne

AU - Poortmans, Philip M.

AU - Spanic, Tanja

AU - Spence, Dingle

AU - Stobart, Hilary

AU - Symmans, Fraser WF

AU - Villarreal-Garza, Cynthia

AU - Yip, Cheng Har

AU - Bienz, Maya J.

AU - Drewett, Lynsey M.

AU - Fulton, Alex

AU - Inbah Rajah, Dharrnesha

AU - Kazmi, Farasat

AU - Rubasingham, Jeffrey

AU - Thompson, Mareike

AU - Vargas, Valentina

AU - Arreola, Hector

AU - Badwe, Raj A.

AU - Calderon Anyosa, Renzo JC

AU - Dave, Rajiv V.

AU - De-Graft Aikins, Ama

AU - Earl, Helena M.

AU - Essue, Beverley M.

N1 - Funding Information: CEC is funded by the National Institute of Health Research (NIHR) and supported by the NIHR Cambridge Biomedical Research Centre. DC reports non-financial interactions unrelated to this Comment with Exact Sciences, Novartis, Lilly, Syntheon, GRAIL, AstraZeneca, Sanofi, Roche, Pfizer, Daiichi-Sankyo, SeaGen, Bexon Consulting, Sapience Therapeutics, and Cytel; research funding unrelated to this Comment, paid to his institution or other institutions, from Amgen, AstraZeneca, Novartis, PFS Exact Sciences, Pfizer, and Roche; and personal fees from AIRC, INCA, SABCS, and Terry Fox Research Institute unrelated to the topic of this Comment. FC reports personal fees from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Debiopharm, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck Sharpe & Dohme, Merus, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, priME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, and Touchime unrelated to the topic of this Comment. FMK is the founding president of Tómatelo a Pecho, a Mexican non-governmental organisation (NGO), and works in a volunteer capacity; Tómatelo a Pecho receives funding from Merck Sharpe & Dohme and Higia. FMK is the senior economist of the Mexican Health Foundation, a Mexican NGO, which receives funding from Fundación Gonzalo Río Arronte, and reports consulting fees from Merck KGaA/EMD Serono unrelated to the topic of this Comment. BOA, RH, MM, and NL declare no competing interests. Financial support for Commission meetings and reimbursement for patient advocates has been provided by Breast Cancer Now. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or WHO.

PY - 2022/3/19

Y1 - 2022/3/19

UR - http://www.scopus.com/inward/record.url?scp=85125787906&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)00184-2

DO - 10.1016/S0140-6736(22)00184-2

M3 - Comment/debate

C2 - 35189077

AN - SCOPUS:85125787906

SN - 0140-6736

VL - 399

SP - 1101

EP - 1103

JO - The Lancet

JF - The Lancet

IS - 10330

ER -